NCT02790723View on ClinicalTrials.gov

Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

June 5, 2019

Primary Completion Date

March 17, 2022

Study Completion Date

March 17, 2022

Conditions

Osteoarthritis, Knee

Interventions

DRUG

sc-rAAV2.5IL-1Ra

Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER